Release Date: 15-Jan-2025
Antibody-drug conjugates (ADCs) represent a promising yet largely untapped commercial opportunity in leukemia treatment. The only ADC currently approved for leukemia is Besponsa (inotuzumab ozogamicin), developed by Pfizer and approved in 2017. Besponsa combines a CD22 monoclonal antibody with the cytotoxic agent calicheamicin, and it is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in patients aged one and above. Despite being the first and only ADC on the market for leukemia, Besponsa has paved the way for further exploration of ADCs in this therapeutic area. Its approval highlights the viability of targeting leukemia cells with ADCs, although commercial uptake remains moderate due to the highly specific patient population it addresses.
Download Report: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
There are currently over 35 ADC candidates in development for leukemia treatment, but most are still in research or preclinical stages. This highlights the challenges of developing ADCs, especially for blood cancers. While there’s a lot of scientific interest and potential, establishing a strong commercial presence will need overcoming challenges like improving effectiveness, reducing toxicity, and targeting more leukemia subtypes. Much of the research is focused on better understanding biomarkers and disease progression to create safer and more effective treatments.
Nevertheless, a few candidates have progressed to early-stage clinical trials, signaling potential breakthroughs in the coming years. Notable examples include Novartis' JBH492, which targets CC chemokine receptor 7 (CCR7), and Merck’s Zilovertamab vedotin, which targets ROR1. Byondis is developing BYON4413, an ADC that targets CD123, while Servier is advancing S227928, an anti-CD74 ADC targeting MCL1. These candidates, while in the early stages, represent a key step forward in developing ADCs that address diverse markers and patient needs within leukemia.
The success of new ADCs will hinge on not just their clinical effectiveness but also how well they stand out from existing treatments and cater to a wider range of patients. Given that leukemia includes many different subtypes, the market will likely stay fragmented until ADCs can effectively target the more common types. Additionally, competition from existing biologics and new therapies like CAR-T cells and bispecific antibodies will influence the market and could restrict the growth of ADCs unless they show better results or meet currently unmet needs.
Thus, the overall landscape for ADCs in leukemia remains nascent, but with a strong pipeline of candidates, there is significant potential for commercial expansion in the future. The market is poised for growth, though timelines will depend on how rapidly these early-stage candidates progress through the clinical phases and secure approvals.